GLPwatch
Bydureon for Alcohol use disorder
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for alcohol use disorder, and any use for this condition is off-label or investigational. A randomized, placebo-controlled clinical trial has investigated exenatide once weekly for alcohol use disorder, and post hoc results examined its effect on pro-inflammatory and metabolic biomarkers in individuals with the condition.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Alcohol use disorder |
| Approval status | Investigational / off-label |
| Research papers | 2 |
Bydureon is not FDA-approved for alcohol use disorder; the research below reflects investigational or off-label study only.
Research on exenatide for alcohol use disorder (2)
- Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
- Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.